NCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
Memorial Sloan Kettering Cancer Center
Mirati Therapeutics Inc.